NCT01161147已完成1 期
Comparative Bioavailability Study of Meloxicam 15 mg Tablets (Dr. Reddy's Laboratories Ltd., Generics) Vs. Mobic® 15 mg Tablets (Boehringer Ingelheim Pharmaceuticals Inc.,Usa) in Healthy Male And/Or Female Volunteers Under Fed Conditions- P1CX04002
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Bioequivalence on Cmax and AUC parameters
研究概览
简要总结
The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Boehringer Ingelheim Pharmaceuticals Inc., USA) under fed conditions.
详细描述
Twenty eight (twenty six study subjects + two alternate subjects)healthy male and/or female subjects participated in an open label, two-period, two-sequence, two- treatment,single dose, two-way crossover study with at least 14 days washout between doses conducted under fed conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The subject must be a healthy male or female volunteer.If the volunteer is female. she must demonstrate β-CG levels consistent with the nongravid state at the medical screening visit and at check-in for Period 1 and agree to remain abstinent or use double-barrier contraception (partner using condom and female volunteer using diaphragm, contraceptive sponge, spermicide, or IUD). If the female is post-menopausal or is surgically sterile, she is exempt from this requirement. (Postmenopausal is defined as no menses for the previous 1 year. If cessation of menses is within 18 months, FSH and/or LH must be documented prestudy as elevated into the postmenopausal range.).
- •The subject must be between the ages of 18 - 55 years old (inclusive).
- •The Subject's body mass index (BMI) must be within 19.0 - 30.0 (Kg/m2).
- •The subject must be a non-smoker and not using any nicotine products.
- •The subject must sign the written consent form (Research Subject Information and Consent Form) prior to study entry.
- •The subject must have clinically acceptable results from the screening procedure including blood pressure, heart rate, ECG, physical exam, medical history, hematology, biochemistry, urinalysis. and infection screen (Hepatitis B Antigen, Hepatitis C Antibody, HIV)
排除标准
- •Subjects with a history of clinically significant gastro-intestinal, dermatological, cardiovascular, renal, hematological, neurological, hepatic, pulmonary, or endocrine disease in the last 12 months.
- •Subjects determined by the Investigator to have any medical condition which may affect the absorption, distribution, metabolism or excretion of the investigational product, or that could jeopardize their health or prejudice the results (e.g. history of surgery of the gastro-intestinal tract, except for appendectomy).
- •Subjects with a known allergy to meloxicam (Mobic) or other nonsteroidal anti-inflammatory drugs (NSAIDS) [e.g. Motrin® (ibuprofen), Celebrex® (celecoxib). Vioxx® (rofecoxib). Naprelan® and Anaprox®, (naproxen sodium), Lodine® (etodolac), Cataflam® (diclofenac potassium). Voltaren® and Arthrotec®(diclofenac sodium), etc.].
- •Females who are pregnant, breastfeeding, or are likely to become pregnant.
- •Subjects with any clinically significant illness within four weeks prior to Period 1 dosing.
- •Subjects with a positive saliva alcohol test at check-in for any period.
- •Subjects with a history of alcohol, drug or substance abuse in the past 12 months.
- •Subjects who have used any prescription medication within 14 days of Period 1 dosing or over-the-counter medication within 14 days of Period 1 dosing.
- •Subjects deemed uncooperative or noncompliant.
- •Subjects who have consumed alcohol within 48 hours prior to Period 1 and Period 2 dosing.
- •Subjects who have consumed xanthine-containing products (including caffeine, theobromines, etc.) within 48 hours prior to Period 1 dosing.
- •Subjects who have consumed food or beverages containing grapefruit (e.g. fresh, Canned, or frozen) within 14 days prior to the administration of the study medication.
- •Subjects who have had an abnormal diet within 30 days prior to Period 1 dosing.
- •Subjects who have participated in an investigational drug study or who have donated more than 100 mL of blood within 30 days prior to Period 1 dosing.
研究组 & 干预措施
Meloxicam
Experimental
Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited
干预措施: Meloxicam (Drug)
Mobic
Active Comparator
Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc
干预措施: Meloxicam (Drug)
结局指标
主要结局
Bioequivalence on Cmax and AUC parameters
时间窗: 4 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting ConditionHealthyNCT01161134Dr. Reddy's Laboratories Limited28
已完成
1 期
Relative Bioavailability of Ambroxol Hydrochloride of Soft Pastilles Compared to Ambroxol Hydrochloride Syrup in Healthy Male and Female VolunteersHealthyNCT02194270Boehringer Ingelheim24
已完成
1 期
A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting ConditionsHealthyNCT00992862Paddock Laboratories, Inc.60
已完成
1 期
Fasting Comparative Bioavailability Study of 2 Meloxicam 15 mg Tablets in Healthy Volunteers Under Fasting ConditionPharmacokineticsNCT05125588Joint Stock Company "Farmak"24
已完成
1 期
Food Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mgHealthyNCT00649675Mylan Pharmaceuticals Inc27